Obesity

Disease State Hub

Podcasts

Endocrinology

Expert Conversations: Endocrine Disruptors, Obesity, and Racial Differences

10/20/2015

In this podcast, Sri Banerjee, MD, PhD, MPH, MAS, Anayra Tua-Lopez, PhD, MPH, and David Harvey, PhD, MPH, speak about the racial differences in the association between endocrine disruptors and obesity,...

10/20/2015

Research Summaries

Research summary

Gastric Bypass Surgery Improves Continued Type 2 Diabetes Remission, Even After Weight Recurrence

03/22/2024

Jessica Ganga

Researchers sought to determine whether patients with type 2 diabetes and obesity experience continued type 2 diabetes remission.

03/22/2024

FDA Alert

FDA Approves Semaglutide For Reducing Serious Cardiovascular Events Among Adults With Heart Disease and Obesity, Overweight

03/21/2024

Anthony Calabro, MA

On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...

03/21/2024

Research Summary

Research Summary

Late-Stage Persistence With Anti-Obesity Medication Varies By Medication, Weight Loss At 6 Months

02/14/2024

Jessica Ganga

Researchers evaluated the early- and later-stage use of various anti-obesity medications in patients.

02/14/2024

Research Summary

Semaglutide Provides Benefits for Patients With HFpEF and Obesity

11/22/2023

Anthony Calabro, MA

Researchers compared the effects of once-weekly semaglutide (2.4 mg) with a placebo during a 52-week period in patients with HFpEF and a BMI of 30 or higher.

11/22/2023

FDA Alert

Tirzepatide Gains FDA Approval for Chronic Weight Management

11/13/2023

Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.

11/13/2023

April 2024

Current Issue

April 2024

Volume 64

Issue 4